United Therapeutics Stock Buy Hold or Sell Recommendation
| UTHR Stock | USD 367.36 3.03 0.83% |
Given the investment horizon of 90 days and your conservative risk appetite, our recommendation regarding United Therapeutics is 'Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell United Therapeutics given historical horizon and risk tolerance towards United Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for United Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out United Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide. Note, we conduct extensive research on individual companies such as United and provide practical buy, sell, or hold advice based on investors' constraints. United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
United |
Execute United Therapeutics Buy or Sell Advice
The United recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on United Therapeutics. Macroaxis does not own or have any residual interests in United Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute United Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
United Therapeutics Trading Alerts and Improvement Suggestions
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Should You Invest in the Invesco Biotechnology Genome ETF |
United Therapeutics Returns Distribution Density
The distribution of United Therapeutics' historical returns is an attempt to chart the uncertainty of United Therapeutics' future price movements. The chart of the probability distribution of United Therapeutics daily returns describes the distribution of returns around its average expected value. We use United Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of United Therapeutics returns is essential to provide solid investment advice for United Therapeutics.
| Mean Return | 0.09 | Value At Risk | -3.07 | Potential Upside | 2.89 | Standard Deviation | 1.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of United Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
United Stock Institutional Investors
The United Therapeutics' institutional investors refer to entities that pool money to purchase United Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Aqr Capital Management Llc | 2024-06-30 | 719.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 621 K | Fuller & Thaler Asset Management Inc | 2024-09-30 | 568.4 K | Pacer Advisors, Inc. | 2024-06-30 | 561.8 K | Alliancebernstein L.p. | 2024-06-30 | 539.6 K | Amundi | 2024-06-30 | 473 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 438.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 434.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 434.5 K | Blackrock Inc | 2024-06-30 | 5.5 M | Vanguard Group Inc | 2024-09-30 | 4.4 M |
United Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 69.2M | 300K | 156.1M | 66.4M | 246.5M | 258.8M | |
| Free Cash Flow | (290.3M) | 696.4M | 477.4M | 663.7M | 747.6M | 785.0M | |
| Other Non Cash Items | (148M) | 191.0M | 72.5M | 23.9M | (1.3M) | (1.2M) | |
| Capital Expenditures | 83.7M | 59.3M | 120.8M | 138.8M | 230.4M | 241.9M | |
| Net Income | (104.5M) | 514.8M | 475.8M | 727.3M | 984.8M | 1.0B | |
| End Period Cash Flow | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
| Depreciation | 35.9M | 45.9M | 49.9M | 51.3M | 53.2M | 55.9M | |
| Change To Inventory | 12.9M | 10.3M | (7.5M) | (13.4M) | (13.6M) | (12.9M) | |
| Investments | (239.2M) | (681.6M) | (366.1M) | (683.6M) | (951M) | (903.5M) | |
| Change Receivables | 121.4M | 24.4M | (6M) | (41.3M) | (25.0M) | (26.2M) | |
| Net Borrowings | (13.2M) | 599.3M | (51.7M) | (7.5M) | (8.6M) | (8.2M) | |
| Change To Netincome | 32.9M | 122.2M | 246.7M | 169.6M | 195.0M | 100.5M |
United Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to United Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that United Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a United stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.01 | |
β | Beta against Dow Jones | 1.06 | |
σ | Overall volatility | 1.74 | |
Ir | Information ratio | -0.0038 |
United Therapeutics Volatility Alert
United Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of 0.0 and Jensen Alpha of -0.01. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure United Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact United Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.United Therapeutics Fundamentals Vs Peers
Comparing United Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze United Therapeutics' direct or indirect competition across all of the common fundamentals between United Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as United Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of United Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare United Therapeutics to competition |
| Fundamentals | United Therapeutics | Peer Average |
| Return On Equity | 0.19 | -0.31 |
| Return On Asset | 0.12 | -0.14 |
| Profit Margin | 0.40 % | (1.27) % |
| Operating Margin | 0.55 % | (5.51) % |
| Current Valuation | 13.18 B | 16.62 B |
| Shares Outstanding | 44.64 M | 571.82 M |
| Shares Owned By Insiders | 1.84 % | 10.09 % |
| Shares Owned By Institutions | 98.16 % | 39.21 % |
| Number Of Shares Shorted | 2.3 M | 4.71 M |
| Price To Earning | 23.49 X | 28.72 X |
| Price To Book | 2.64 X | 9.51 X |
| Price To Sales | 5.90 X | 11.42 X |
| Revenue | 2.33 B | 9.43 B |
| Gross Profit | 1.78 B | 27.38 B |
| EBITDA | 1.39 B | 3.9 B |
| Net Income | 984.8 M | 570.98 M |
| Cash And Equivalents | 2.26 B | 2.7 B |
| Cash Per Share | 49.55 X | 5.01 X |
| Total Debt | 700 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 8.10 X | 2.16 X |
| Book Value Per Share | 136.74 X | 1.93 K |
| Cash Flow From Operations | 978 M | 971.22 M |
| Short Ratio | 7.51 X | 4.00 X |
| Earnings Per Share | 22.76 X | 3.12 X |
| Price To Earnings To Growth | 1.56 X | 4.89 X |
| Target Price | 382.29 | |
| Number Of Employees | 1.17 K | 18.84 K |
| Beta | 0.56 | -0.15 |
| Market Capitalization | 16.27 B | 19.03 B |
| Total Asset | 7.17 B | 29.47 B |
| Retained Earnings | 6.03 B | 9.33 B |
| Working Capital | 2.75 B | 1.48 B |
Note: Disposition of 237 shares by Michael Benkowitz of United Therapeutics at 362.0202 subject to Rule 16b-3 [view details]
United Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as United . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About United Therapeutics Buy or Sell Advice
When is the right time to buy or sell United Therapeutics? Buying financial instruments such as United Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having United Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.